Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years

Buti M., Fung S., Gane E., Afdhal N. H., Flisiak R., GÜREL S., ...Daha Fazla

HEPATOLOGY INTERNATIONAL, cilt.9, sa.2, ss.243-250, 2015 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 9 Sayı: 2
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1007/s12072-015-9614-4
  • Dergi Adı: HEPATOLOGY INTERNATIONAL
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.243-250
  • Anahtar Kelimeler: Antiviral agent, Chronic hepatitis B, Cirrhosis, Hepatitis B e antigen, Hepatitis B surface antigen, Tenofovir disoproxil, HEPATOCELLULAR-CARCINOMA, ADEFOVIR DIPIVOXIL, FOLLOW-UP, LAMIVUDINE, REGRESSION, THERAPY, DISEASE, LEVEL, RISK
  • Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Phase 3 clinical studies have shown that long-term treatment with tenofovir disoproxil fumarate (TDF) can suppress hepatitis B viral load and promote significant fibrosis regression and cirrhosis reversal in a majority of treated chronic hepatitis B (CHB) patients. This retrospective analysis investigated the impact of baseline cirrhosis status on virologic, serologic, and histologic outcomes in patients treated with TDF.